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Dialysis-requiring acute kidney injury (AKI) is associated with substantial mortality and risk
of end-stage renal disease (ESRD). Despite considerable growth in incidence of severe
AKI, information pertaining to trends in outcomes remains limited. We evaluated time trends
in one year risks of ESRD and death in patients with dialysis-requiring AKI over an eight
year period in Denmark.
Methods
In a retrospective nationwide study based on national registers, all adults requiring acute
renal replacement therapy between 2005 and 2012 were identified. Patients with preceding
ESRD were excluded. Through individual-level cross-referencing of administrative regis-
tries, information pertaining to comorbidity, preceding surgical interventions, and concurrent
other organ failure and sepsis was ascertained. Comparisons of period-specific one year
odds ratios for ESRD and death were calculated in a multiple logistic regression model.
Results
A total of 13,819 patients with dialysis-requiring AKI were included in the study. Within one
year, 1,017 (7.4%) patients were registered with ESRD, and 7,908 (57.2%) patients died.
The one-year rate of ESRD decreased from 9.0% between 2005 and 2006 to 6.1% between
2011 and 2012. Simultaneously, the one-year mortality rate decreased from 58.2%
between 2005 and 2006 to 57.5% between 2011 and 2012. Consequently, the adjusted
odds ratios for the period 2011–2012 (with the period 2005–2006 as reference) were 0.75
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(0.60–0.95, p = 0.015) and 0.87 (95% CI 0.78–0.97, p = 0.010) for ESRD and death,
respectively.
Conclusions
In a nationwide retrospective study on time trends in one year outcomes following dialysis-
requiring AKI, risk of all-cause mortality and ESRD decreased over a period of 8 years.
Introduction
Acute kidney injury (AKI) continues to be a severe disease associated with poor prognosis [1,
2]. AKI is independently associated with diminished short- and long-term survival [3–5], and
outcomes are proportional to AKI severity [6, 7]. Additionally, AKI is associated with substan-
tially increased propensity for chronic kidney disease (CKD) including end-stage renal disease
(ESRD) [8–11]. Crude incidence rates of dialysis-requiring AKI have increased substantially
throughout the last two decades [12, 13]; however, Danish incidence rates have remained stable
at approximately 350 per million since 2006 [14], and information pertaining to temporal
change in outcomes following AKI continues to be limited [15, 16]. Development of AKI is
predominantly characterized by concurrence of acute and chronic disease [17, 18]. Conse-
quently, risk prediction in AKI is dependent on an accurate comprehension of the interplay
between potential risk factors for adverse outcomes. The clinical implications associated with
changing employment of acute renal replacement therapy (RRT) however remain undeter-
mined. Accordingly, the aim of the present study was to investigate temporal change in out-
comes following dialysis-requiring AKI. Consequently, we assessed one-year risk for ESRD




Danish residents are issued a civil registration number at birth or time of immigration. As
health services are tax-funded; all Danish citizens receive comprehensive medical coverage
through the public health care system. Treatment is registered according to the civil registra-
tion number, and consequently, cross-referencing of registers is possible. Information concern-
ing public health care is recorded in multiple national administrative registers. All
hospitalizations are recorded in the National Patient Registry, and reimbursement is contin-
gent on accurate registration by departments. Diagnostic coding is registered in accordance
with the 10th edition of the International Classification of Diseases (ICD), and procedural cod-
ing is registered in accordance with the Nordic Medico-Statistical Committee Classification of
Surgical Procedures [19, 20]. The predicative value of diagnostic codes included in the Charl-
son Index Score has recently been validated with excellent results [21]. Additionally, chronic
dialysis treatment and renal transplantations are recorded in the validated Danish National
Registry on Regular Dialysis and Transplantation [22]. Dispensation of prescription medica-
tion by Danish pharmacies is recorded in the Danish Register of Medicinal Product Statistics
[23]. The register records the Anatomical Therapeutic Chemical Classification System (ATC)
code, quantity, strength and date of all prescriptions dispensed in Danish pharmacies. Prescrip-
tion medication is partially reimbursed by the public healthcare system, and the register has
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been validated with excellent results [23, 24]. Limited biochemistry was available for a fraction
of the study population; results were accessible from multiple laboratories across Denmark.
Finally, information relating mortality and causes of death was determined via the National
Registry of Causes of Death [25].
Study Population
Dialysis-requiring AKI was defined as treatment with acute RRT in patients without previously
registered chronic RRT. All patients requiring acute RRT between 1st January 2005 and 31st
December 2012 were identified in the Danish National Patient Registry. Patients<18 years
old, patients migrating within one year of treatment, patients previously treated with acute
RRT, and patients previously registered with chronic RRT were excluded. All patients were fol-
lowed until an endpoint or the end of the study. A flow chart depicting study design is shown
in Fig 1.
Study Outcomes
Primary outcomes were defined as all-cause mortality and ESRD at one year. Secondary out-
comes were defined as estimated glomerular filtration rate (eGFR) (plasma creatinine measure-
ments recorded 52–104 weeks following index) in survivors with preserved renal function at
one year, duration of dialysis-requirement, and duration of hospital admission.
Study Covariates
Comorbidities were identified based on diagnostic codes found in the National Patient Regis-
try. Sensitivity for hypertension, and diabetes was augmented through the inclusion of infor-
mation pertaining to outpatient medication. Preceding eGFRs were calculated as means all
available plasma creatinine measurements recorded 52 to 2 weeks prior to index in accordance
with the Chronic Kidney Disease Epidemiology Collaboration equation [26]. Azotemic param-
eters registered one day prior to index were included where available. Major cardiothoracic,
gastric and orthopedic surgical interventions were identified based on procedural codes found
in the National Patient Registry. Post-procedural dialysis-requirement was defined as acute
RRT within 14 days of a major surgical intervention. Dialysis modalities were identified based
on procedural codes found in the National Patient Registry as continuous RRT (CRRT), acute
intermittent hemodialysis, or acute peritoneal dialysis. Similarly, requirements of mechanical
ventilation and/or circulatory support were also identified based on procedural codes found in
the National Patient Registry. Outpatient medications as baseline were identified in the pre-
scription database. A comprehensive list of the medications, relevant codes, and algorithms are
provided in S1 Appendix.
Statistical Analysis
Outcomes following dialysis-requiring AKI were compared between the periods; 2005–2006,
2007–2008, 2009–2010, and 2011–2012. Trends in patient characteristics were compared using
the Cochrane-Armitage test. Durations of dialysis-requirement and hospital stay amongst
patients surviving beyond hospital discharge were calculated in whole days in renal survivors.
Statistical significance was defined as a two sided p-value<0.05. Analyses were performed
using SAS software (versions 9.4, SAS Institute), and R version 2.15.2 (R Development Core
Team). Summary results were reported with 95% confidence intervals (CI), means with stan-
dard deviations (SD), and medians with interquartile range (IQR). Odds ratios for one-year
mortality and ESRD were calculated in multiple logistic regression analyses with adjustment
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for known risk factors associated with prognosis. As such, the models were adjusted for patient
age, gender, dialysis modality, comorbidity, surgery, sepsis, mechanical ventilation, and circu-
latory support. Comorbidities included in the model were; non-insulin dependent and insulin-
dependent diabetes, congestive heart failure, ischemic heart disease, cardiac arrhythmia, valvu-
lar heart disease, peripheral vascular disease, stroke, chronic obstructive pulmonary disease,
solid and non-solid cancer, and chronic kidney disease. Preceding surgeries included in the
model were any major cardiothoracic, gastric or orthopedic procedures.
Furthermore, odds ratios for one-year mortality and ESRD were also computed in various
selected subpopulations. These included; gender-specific strata, age-specific strata, modality-
specific strata, non-surgery-related and surgery-related strata, non-intensive care requiring
and intensive care requiring strata, and Charlson Index Score stratified (<3, 3–6, and>6). In
Fig 1. Flow chart depicting study design.
doi:10.1371/journal.pone.0159944.g001
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additional analyses, odds ratios were calculated for 90-day mortality and 90-day renal survival
using multiple logistic regression analyses analogous to the principal analyses. As incidence of
dialysis-requiring AKI in the general population was lowest in 2005, sensitivity analyses with
exclusion of patients from the aforementioned year were performed to confirm the principal
results; no differences were discernable. Finally, residual renal function was assessed in renal
survivors by comparing the proportionate number of patients with significant (>20%) decrease
in eGFR 90–365 days following index. Retrospective register based studies do not need ethical
approval in Denmark; however, the Danish Data Protection Agency has approved use of data
(ref. 2007-58-015 / I-suite nr 00916 GEH-2010-001).
Results
A total of 13,819 patients with dialysis-requiring AKI were identified between January 1st 2005
and December 31st 2012. Although patient characteristics principally remained stable, use of
CRRT and mechanical ventilation increased over time. Period-specific baseline characteristics
are shown in Table 1.
Preceding eGFRs were available in 16.5% (n = 2,286) of patients; period-specific eGFRs
were; 55 ml/min/1.73m2 [IQR 33–76], 57 ml/min/1.73m2 [IQR 37–75], 60 ml/min/1.73m2
[IQR 41–81], and 66 ml/min/1.73m2 [IQR 42–86] for the periods 2005–2006, 2007–2008,
2009–2010, and 2011–2012, respectively (p<0.001). The median time from admission to initia-
tion of dialysis decreased; the period-specific intervals were 6 [IQR 1–18], 5 [1–14], 5 [1–14],
and 4 [1–13] for the periods 2005–2006, 2007–2008, 2009–2010, and 2011–2012, respectively
(p<0.001). Additionally, blood samples pertaining to dialysis indications were available in a
limited number of patients at index; results are shown in Table 2.
Within one year of dialysis-requiring AKI, 1,017 patients were registered with ESRD, and
7,908 patients died, corresponding to an absolute one-year rate of 7.4% and 57.2% for ESRD
and death, respectively. Prevalence of ESRD in renal survivors only was 17.2%. Period-specific
unadjusted one-year mortality rates were 58.2% (n = 1,799), 56.3% (n = 1,981), 57.1%
(n = 2,081), and 57.5% (2,047) for the periods 2005–2006, 2007–2008, 2009–2010, and 2011–
2012, respectively (p = 0.470). Period-specific unadjusted one year rates of ESRD were 11.1%
(344), 9.2% (488), 14.9% (240), and 6.6% (354) for the periods 2005–2006, 2007–2008, 2009–
2010, and 2011–2012, respectively (p<0.001).
Overall, adjusted odds ratios for ESRD and death decreased incrementally over time. The
adjusted one-year risk of death decreased by 3.8% [2.1–5.4] per year (p = 0.001), and the
adjusted one-year risk of ESRD decreased by 6.6% [3.3–9.8] per year (p = 0.009). Odds ratios
for one-year risk of death and ESRD are shown in Figs 2 and 3, respectively. Notably, mortality
remained essentially unchanged in women, patients>80years, and in patients with Charlson
Index score>6; however, ESRD prognosis for all subpopulations improved in all subpopula-
tions. No significant interaction was determined between period and gender, period and
patient age, and period and dialysis modality. Odds ratios for one-year risk of death and ESRD
in subpopulations are shown in Figs 4 and 5. Improvement in short-term risk of death and
ESRD was also observed. Odds ratios for 90-day mortality were 0.90 (0.81–1.00), 0.94 (0.84–
1.04), and 0.86 (0.77–0.96), and odds ratios for 90-day risk of ESRD were 0.92 (0.75–1.12), 0.81
(0.66–1.00), and 0.76 (0.61–0.95) for the periods 2007–2008, 2009–2010, and 2011–2012,
respectively (with 2005–2006 as reference).
Preceding and succeeding eGFRs were available in a total of 493 of 5,911 renal survivors.
Overall, a20% decreased in eGFR following dialysis-requiring AKI was observed in 43.2%
(213) patients in the subsample; the period-specific proportions of patients with a20%
decrease in eGFR were 51.2%, 41.1%, 38.2%, and 43.6% for the periods 2005–2006, 2007–2008,
Trends in Outcomes following Dialysis-Requiring AKI
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2009–2010, and 2011–2012, respectively (p = 0.125). Durations of dialysis-requirement
decreased over time; the period-specific median requirements were 13 days [IQR 6–25], 12
days [IQR 5–24], 12 days [IQR 6–23], and 12 days [IQR 6–22], for the periods 2005–2006,
2007–2008, 2009–2010, and 2011–2012, respectively (p<0.001). Durations of hospital admis-
sion also decreased over time; the period-specific median requirements were 70 days [IQR 34–
Table 1. Period-specific baseline characteristics of patients with dialysis-requiring AKI in Denmark between 2005 and 2012.
Variables 2005–2006 2007–2008 2009–2010 2011–2012
n = 3.093 n = 3,521 n = 3,642 n = 3.563 p-value
Characteristics
Gender (male), n (%) 2022 (65.4) 2164 (61.5) 2264 (62.2) 2227 (62.5) 0.007
Age (years) median [IQR] 69.0 [59.2–76.3] 68.1 [58.6–76.0] 68.6 [59.3–76.3] 69.0 [60.0–76.9] 0.002
Comorbidities
Cardiac arrhythmia (%) 691 (22.3) 720 (20.4) 813 (22.3) 867 (24.3) 0.002
Chronic kidney disease, n (%) 827 (26.7) 900 (25.6) 892 (24.5) 876 (24.6) 0.126
Chronic obstructive pulmonary disease, n (%) 339 (11.0) 385 (10.9) 375 (10.3) 425 (11.9) 0.174
Diabetes, n (%) 667 (21.6) 835 (23.7) 955 (26.2) 977 (27.4) <0.001
Heart failure, n (%) 496 (16.0) 438 (12.4) 481 (13.2) 512 (14.4) <0.001
Ischemic heart disease, n (%) 708 (22.9) 653 (18.5) 696 (19.1) 681 (19.1) <0.001
Liver disease, n (%) 247 (8.0) 325 (9.2) 350 (9.6) 344 (9.7) 0.069
Non-solid cancer (%) 166 (5.4) 196 (5.6) 225 (6.2) 208 (5.8) 0.506
Peripheral vascular disease, n (%) 369 (11.9) 401 (11.4) 365 (10.0) 359 (10.1) 0.022
Solid cancer (%) 461 (14.9) 510 (14.5) 584 (16.0) 564 (15.8) 0.217
Stroke, n (%) 456 (14.7) 517 (14.7) 517 (14.2) 500 (14.0) 0.792
Valvular heart disease (%) 331 (10.7) 346 (9.8) 405 (11.1) 429 (12.0) 0.027
Charlson Index Score
Charlson Score <3 (%) 323 (10.4) 434 (12.3) 393 (10.8) 372 (10.4) 0.098
Charlson Score 3–6 (%) 1591 (51.4) 1790 (50.8) 1895 (52.0) 1890 (53.0)
Charlson Score >6 (%) 1179 (38.1) 1297 (36.8) 1354 (37.2) 1301 (36.5)
Hospital admission
Continuous renal replacement therapy, n (%) 1499 (48.5) 1858 (52.8) 2057 (56.5) 2094 (58.8) <0.001
Acute intermittent hemodialysis, n (%) 1576 (51.0) 1649 (46.8) 1576 (43.3) 1445 (40.6)
Acute peritoneal dialysis, n (%) 18 (0.6) 14 (0.4) 9 (0.2) 24 (0.7)
Admission to intensive care, n (%) 2193 (70.9) 2487 (70.6) 2665 (73.2) 2640 (74.1) 0.002
Mechanical ventilation, n (%) 2010 (65.0) 2279 (64.7) 2434 (66.8) 2395 (67.2) 0.059
Circulatory support, n (%) 851 (27.5) 964 (27.4) 945 (25.9) 868 (24.4) 0.009
Sepsis, n (%) 760 (24.6) 887 (25.2) 930 (25.5) 778 (21.8) <0.001
Cardiac surgery (%) 447 (14.5) 370 (10.5) 434 (11.9) 479 (13.4) <0.001
Gastric surgery (%) 485 (15.7) 532 (15.1) 482 (13.2) 503 (14.1) 0.022
Orthopedic surgery (%) 160 (5.2) 174 (4.9) 191 (5.2) 180 (5.1) 0.942
Outpatient medication
Insulin (%) 243 (7.9) 313 (8.9) 348 (9.6) 351 (9.9) 0.025
Loop diuretics (%) 929 (30.0) 1063 (30.2) 1062 (29.2) 1113 (31.2) 0.293
Thiazides (%) 409 (13.2) 507 (14.4) 551 (15.1) 501 (14.1) 0.162
Aldosterone antagonist (%) 267 (8.6) 278 (7.9) 287 (7.9) 298 (8.4) 0.611
Renin-angiotensin system blocking treatment, n (%) 869 (28.1) 1067 (30.3) 1199 (32.9) 1191 (33.4) <0.001
Lipid-lowering treatment, n (%) 651 (21.0) 865 (24.6) 1071 (29.4) 1077 (30.2) <0.001
Non-steroidal anti-inﬂammatory drugs (%) 342 (11.1) 361 (10.3) 340 (9.3) 301 (8.4) 0.002
Proton-pump inhibitors (%) 619 (20.0) 780 (22.2) 859 (23.6) 911 (25.6) <0.001
doi:10.1371/journal.pone.0159944.t001
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111], 63 days [IQR 24–104], 63 days [IQR 30–108], and 54 days [IQR 26–96], for the periods
2005–2006, 2007–2008, 2009–2010, and 2011–2012, respectively (p<0.001).
Discussion
In this nationwide retrospective study on outcomes following dialysis-requiring AKI, prognosis
was observed to improve incrementally during an eight year study period. Specifically, the
Table 2. Period-specific baseline azotemia and lactate parameters.
Variables n 2005–2006 2007–2008 2009–2010 2011–2012 p-value
Serum creatinine (μmol/L), median [IQR] 1,553 346 [188–559] 338 [183–565] 319 [156–562] 378 [188–595] 0.408
Serum K+ (mEq/L), median [IQR] 1,550 4.3 [3.7–4.9] 4.2 [3.7–4.8] 4.3 [3.8–4.9] 4.2 [3.6–4.9] 0.301
Serum HCO3- (mEq/L), median [IQR] 287 17.1 [15.3–20.4] 18.3 [14.9–2.6] 16.1 [12.9–19.5] 16.5 [13.4–19.9] 0.056
Serum Lactate (mEq/L), median [IQR] 165 2.0 L [1.1–2.0] 1.6 [1.2–2.3] 2.2 [1.3–6.1] 2.5 [1.4–4.9] 0.048
doi:10.1371/journal.pone.0159944.t002
Fig 2. Period-specific one-year risk of death.Multivariable logistic regression model adjusted for patient age, gender, dialysis modality,
comorbidity, surgery, sepsis, mechanical ventilation, and circulatory support.
doi:10.1371/journal.pone.0159944.g002
Fig 3. Period-specific one year risk of end-stage renal disease.Multivariable logistic regression model adjusted for patient age, gender, dialysis
modality, comorbidity, surgery, sepsis, mechanical ventilation, and circulatory support.
doi:10.1371/journal.pone.0159944.g003
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Fig 4. Period-specific one year risk of death in subgroups.Multivariable logistic regression model adjusted for patient age, gender, dialysis
modality, comorbidity, surgery, sepsis, mechanical ventilation, and circulatory support. CRRT = Continous renal replacement therapy.
IHD = Intermitted hemodialysis.
doi:10.1371/journal.pone.0159944.g004
Trends in Outcomes following Dialysis-Requiring AKI
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Fig 5. Period-specific one year risk of end-stage renal disease in subgroups.Multivariable logistic regression model adjusted for patient age,
gender, dialysis modality, comorbidity, surgery, sepsis, mechanical ventilation, and circulatory support. CRRT = Continous renal replacement
therapy. IHD = Intermitted hemodialysis.
doi:10.1371/journal.pone.0159944.g005
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odds ratio of both all-cause mortality and ESRD was observed to decrease by ~20% between
2005 and 2012. Simultaneously, durations of dialysis-requirement and hospitalization
decreased. Irrespectively, prognosis following dialysis-requiring AKI remains unfavorable,
with only approximately one third of patients surviving without requiring chronic RRT. AKI is
associated with significant mortality, with one-year mortality rates fluctuating from ~35% to
~70% dependent on population and AKI severity [4, 27–29]. However, mortality rates have
been reported to be decreasing [13, 15, 16, 30, 31], although the attributable risk for death asso-
ciated with AKI may be increasing [32]. Additionally, AKI survivors remain at increased risk
of ESRD. Reported rates of ESRD range from 2% to 20% [3, 5, 8, 15, 33, 34]; however, risk of
ESRD following dialysis-requiring AKI—as is the case with mortality—could be decreasing
[15]. Regardless, our results indicate incremental improvement in prognosis following dialysis-
requiring AKI from 2005 till 2012.
Although initiation of acute RRT in the context of imminent indications is associated with
poorer outcomes [35], evidence supporting early initiation of acute RRT in AKI remains
wholly insufficient [36]. Accordingly, initiation of acute RRT continues to be based on immi-
nent indications with no apparent shift towards earlier initiation of therapy [37, 38]. Our
results corroborate this observation, as we were unable to document any substantial change in
pre-dialysis azotemia or serum lactate. Furthermore, incidence rates of non-dialysis-requiring
AKI have increased throughout the last decade, while incidence rates of dialysis-requiring AKI
have remained stable [14]. As such, no existing evidence clearly substantiates changing thresh-
olds for initiation of acute RRT.
Although no novel interventions pertaining to dialysis-requiring AKI have demonstrated
genuine benefit throughout the last decade [39–43], our results nonetheless provide further evi-
dence of increments in survival and renal recovery following severe AKI. Use of CRRT
increased throughout the study period. Dialysis-modality has previously been demonstrated to
be associated with outcomes in observational data [38]; however, the association is plausibly
driven by selection biases, and no evidence currently supports any benefit associated with a
specific modality [44–48]. Improvements in prognoses could alternately represent the benefi-
cial effects related to implementation of evidence-based goal-directed therapy in critical illness
[49, 50]. Outcomes following sepsis and septic shock are known to be improving [51, 52], pos-
sibly due to the benefits associated with the surviving sepsis guidelines [53], and outcomes fol-
lowing acute respiratory failure may also be improving [54]; albeit, thresholds for use of
mechanical ventilation could be changing [55]. As such, the observed improvement of out-
comes following dialysis-requiring AKI remains plausible, although possibly driven by inter-
ventions targeting supportive and non-kidney related care.
Our results confirm the detrimental consequences associated with severe AKI. Initial survi-
vors of dialysis-requiring AKI remain at substantially increased risk of ESRD. Tentatively, our
results indicate an improvement in residual eGFR in non-ESRD survivors; however, as preced-
ing and succeeding eGFRs were only available in a small fraction of our population, the analysis
was both underpowered and plausibly subject to certain biases. While outpatient care holds
potential in identifying CKD in time to mitigate complications, only a fraction of patients with
dialysis-requiring AKI are currently referred to a nephrologist following discharge [56, 57].
Notably, referral to a nephrologist following discharge is associated with interventions [58],
and improved outcomes in retrospective cohorts [59].
Our study had numerous strengths. First, due to the structure of public health care in Den-
mark, national registries record comprehensive information pertaining to medical care of all
Danish citizens. Follow-up is generous and essentially unflawed, and national registries are
extensively validated. Second, the availability of reliable data from the Danish National Registry
on Regular Dialysis and Transplantation ensures an accurate dissemination between dialysis-
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requiring AKI and acute RRT in ESRD. Additionally, the accuracy of CRRT in the intensive
care setting has previously been validated with excellent results [60]. However, our study also
had a number of limitations. First, correlation is not causation; due to the observational design,
our results do not provide definite answers related to cause. Second, the absence of systematic
and universal laboratory and clinical data is regrettable; consequently, a number of possible
confounders remain unaddressed. Specifically, the limited data on biochemical and clinical
indications for initiating acute RRT remains unfortunate; particularly as the availability of data
pertaining to baseline azotemia was underpowered for definite conclusions regarding clinical
implications. Furthermore our algorithm for identification of dialysis-requiring AKI does not
rule out alternate indications for acute RRT to AKI. Additionally, prevalence of comorbidity
may be underestimated due to a reliance on diagnostic and procedural coding. Finally, due to
the particular demographics of Denmark, results cannot necessarily be extrapolated to other
populations.
Conclusions
In a nationwide retrospective study on outcomes within the first year following dialysis-requir-
ing AKI, we observed incremental decrease in odds ratios for all-cause mortality and ESRD
between 2005 and 2012. Although mortality of patients with greatest vulnerability and women
remained unchanged, an overall improvement in outcomes following dialysis-requiring AKI of
all patients was observed. Although interpretation of our results is subject to limitations per-
taining to residual confounding, dialysis-requiring AKI nonetheless continues to be associated
with disheartening prognoses, with current one-year mortality and ESRD rates exceeding 50%
and 10%, respectively.
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